Psychedelics Investors wince as FDA panel rejects proposal to approve ‘molly’ for PTSD therapy Despite rejection from the advisory committee, the FDA won't make its final decision on the matter until August Rowan DunneJune 5, 2024
Cannabis Delta-8 vs Delta-9 THC: What’s The Difference? Although both compounds are found in the cannabis plant, there are significant differences in their effects and legislation Adeline EeMay 22, 2024
Technology Inspira Technologies seeks FDA approval for cardiopulmonary device The ALICE incorporates several of Inspira's features and capabilities into one handy device Joseph MortonDecember 20, 2022
Psychedelics Silo Pharma prepares pre-IND package for FDA on novel ketamine formulation Company will collaborate with Premier Consulting as regulatory partner and utilize Zylö Therapeutics Z-Pod technology Rowan DunneOctober 3, 2022
Medical and Pharmaceutical IceCure Medical aims to bring cold cancer treatment to Vietnam Liver, lung and breast cancer were the three most prevalent cancers in Vietnam in 2020, according to the World Health Organization. Joseph MortonAugust 31, 2022
Sleep Inspire Medical Systems recruits top tier investor relations talent Yagci brings over 15 years experience as an institutional investor in medical devices and healthcare services to the table. Joseph MortonAugust 22, 2022
Psychedelics Phillips Lytle announces the inception of its Psychedelic & Mental Health Therapies Practice New York law firm forms multidisciplinary association intended to serve the psychedelic industry Rowan DunneAugust 19, 2022
Business The Mugglehead technology roundup: glowing health edition Here are five companies looking to improve our collective health in different ways. Joseph MortonJune 17, 2022
Cannabis Tetra Bio-Pharma enters Australia via new subsidiary acquisition Canadian company set to focus clinical trials down under, announces regulatory update Rowan DunneJune 6, 2022
Business MediPharm Labs to enter US pharmaceutical market via FDA drug registration If approved, it could advance the firm's goal of becoming a dominant supplier of cannabinoid pharmaceutical ingredients Natalia Buendia CalvilloFebruary 23, 2022